Jazz Pharmaceuticals
JAZZ
454 hedge funds and large institutions have $7.29B invested in Jazz Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 136 increasing their positions, 168 reducing their positions, and 68 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1.08% more ownership
Funds ownership: 92.94% → 94.02% (+1.1%)
9% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 68
0% less funds holding
Funds holding: 455 → 454 (-1)
1% less capital invested
Capital invested by funds: $7.39B → $7.29B (-$93.9M)
19% less repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 168
59% less call options, than puts
Call options by funds: $34.2M | Put options by funds: $83.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$149M |
| 2 |
AC
Armistice Capital
New York
|
+$72.8M |
| 3 |
Millennium Management
New York
|
+$57.9M |
| 4 |
JP Morgan Chase
New York
|
+$42.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$194M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$100M |
| 3 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
-$59.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$42.8M |
| 5 |
Renaissance Technologies
New York
|
-$39.2M |
JAZZ Hedge Fund Activity: Q4 2021 in Review
454 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2021, worth a combined $7.29B — down 1.3% from $7.39B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new JAZZ positions and 68 closed out — a net gain of 6 holders — while 136 added to existing stakes and 168 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $149M. The largest seller was Fidelity Investments, cutting an estimated $194M.
- 454 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2021, down from 455 in Q3 2021.
- Funds reported $7.29B of Jazz Pharmaceuticals stock for Q4 2021, down 1.3% quarter-over-quarter.
- 74 funds opened new Jazz Pharmaceuticals positions in Q4 2021 and 68 closed out, a net change of +6 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2021 was Goldman Sachs, an estimated $149M added.
- The largest Jazz Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $194M sold.
Based on aggregated 13F filings for Q4 2021.